Journal
NEW ENGLAND JOURNAL OF MEDICINE
Volume 383, Issue 5, Pages 460-473Publisher
MASSACHUSETTS MEDICAL SOC
DOI: 10.1056/NEJMra1908213
Keywords
-
Categories
Ask authors/readers for more resources
Treatment of CLL, the most common leukemia in the West, has undergone a revolution in the past few years with the development of agents that target signaling kinases and cell-survival mediators. Survival even among patients with a poor prognosis now exceeds 8 years.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
